Data presentations will deepen understanding of the options Zejula (niraparib) and Jemperli (dostarlimab) bring in treating ovarian and endometrial cancers in certain patients
GlaxoSmithKline (GSK) plc will present new findings in support of advancing treatment for certain gynaecologic cancers, including data evaluating Zejula (niraparib) and Jemperli (dostarlimab) at the upcoming Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. The meeting will take place in Phoenix, Arizona, and virtually from 18-21 March 2022. The presentations demonstrate GSK’s commitment to improving outcomes for patients with gynaecologic cancers through research programmes that identify and address high unmet patient needs.

Hesham Abdullah, Global Head of Oncology Development, GSK said: “The data we’re presenting at SGO will provide the research community with deeper insights about Zejula and Jemperli. We will also share data that furthers our understanding of ovarian and endometrial cancers, and real-world data that sheds light on potential gaps in the care of patients with gynaecologic cancer that need to be addressed.”

Exploring optimal use of PARP inhibition maintenance therapy in ovarian cancer

Research being presented at SGO reinforces the role of first-line maintenance therapy with poly (ADP-ribose) polymerase (PARP) inhibitors in helping to optimise treatment outcomes for patients living with advanced ovarian cancer. This data contributes to the understanding of niraparib in the maintenance treatment of ovarian cancer.

Key oral presentations include:

OVARIO (oral presentation, ID #39): an oral plenary presentation featuring an updated analysis from this phase II study evaluating niraparib in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer following platinum-based chemotherapy and bevacizumab.
ROYAL (oral presentation, ID #28): an oral plenary presentation featuring a real-world evidence study examining the evolution of the ovarian cancer treatment paradigm in the US and Europe from 2017 to 2020. The findings may help us better understand the treatment paradigm of ovarian cancer and identify remaining unmet needs.
In addition, Zai Lab (a GSK partner) will present a late-breaking oral presentation of the phase III PRIME study (late-breaking oral presentation, ID #5), featuring data evaluating niraparib (independently manufactured by Zai Lab) in Chinese patients with newly diagnosed advanced ovarian cancer using an individualized starting dose.

As part of GSK’s ongoing commitment to the ovarian cancer community, additional real-world studies assessing unmet needs will also be presented, including a study evaluating trends in first-line maintenance treatment use in patients with newly diagnosed advanced ovarian cancer, a study evaluating outcomes in patients with recurrent ovarian cancer who received niraparib as second-line maintenance therapy, and a study that assessed trends in niraparib starting dose as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Zejula is a once-daily oral monotherapy maintenance treatment approved for women with first-line platinum-responsive (complete or partial response) advanced ovarian cancer regardless of biomarker status in the US and the European Union (EU).

Advancing standard of care treatment in endometrial cancer

Key dostarlimab presentations at SGO include:

GARNET trial subgroup (poster presentation, ID #210): a post-hoc analysis from the GARNET trial evaluating the antitumour activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups. This analysis will provide insights on outcomes in an older endometrial cancer patient population, potentially helping to inform treatment decisions.
Dostarlimab indirect treatment comparison (poster presentation, ID #216): an analysis comparing the clinical effectiveness of dostarlimab with doxorubicin in the treatment of advanced or recurrent endometrial cancer, which may help further contextualize how dostarlimab fits in the recurrent or advanced dMMR endometrial cancer treatment landscape.
The GARNET trial was the basis for the US and EU regulatory approvals of Jemperli, a programmed cell death receptor-1 (PD-1) blocking antibody.

Jemperli is the first anti-PD-1 monotherapy approved for endometrial cancer in the EU and received a conditional approval in April 2021 for the treatment of women with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum-containing regimen. The treatment also received accelerated approval based on tumour response rate and durability of response in the US for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, who have progressed on or following prior treatment with a platinum-containing regimen. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Full list of GSK’s presentations at SGO for niraparib and ovarian cancer:
see & read more on
https://www.gsk.com/en-gb/media/press-releases/gsk-to-demonstrate-its-commitment-to-improving-outcomes-for-patients-with-gynaecologic-cancer-at-the-2022-sgo-annual-meeting/